Analysis of the clinical effects and changes in serum NSE,Hcy and T cell 17 levels during the adjuvant treatment of epilepsy in children with sodium valproate
Objective To analyze the clinical effect of sodium valproate in the adjuvant treatment of children with epilepsy,as well as its impact on the changes in serum neuron specific enolase(NSE),homo-cysteine(Hcy)and T cell 17 level(Th17). Methods A total of 152 children with epilepsy were admitted to Handan Second Hospital from January 2020 to March 2023. They were selected for the study and divided into two groups based on their treatment regimens:acontrol group of 73 cases(treated with topiramate)and an observation group of 79 cases(treated with sodium valproate+topiramate). Thestudy compared the overall efficacy rate,levels of inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-2(IL-2),Hcy], brain-derived neurotrophic factor(BDNF),NSE,Th17 levels and adverse reactions between the two groups. Results The total curative effect rate of the control group was 75.29％,while the observation group had a higher rate of 91.81％. This difference was statistically significant (P<0.05). After treatment,both groups showed a decrease in the levels of TNF-α,IL-2,NSE,Hcy and Th17. The observation group had lower levels of these markers compared to the control group,and this difference was statistically significant(P<0.05). The level of BDNF increased in both groups after treatment ,with the observation group having a higher level than the control group. This difference was statistically significant (P<0.05). The total incidence of adverse reactions in the control group was 9.59％,while the observation group had a lower rate of 5.04％. However,this difference was not statistically significant(P>0.05). Conclusion The clinical efficacy of sodium valproate assisted topiramate in the treatment of children with epilepsy is excellent. This combination effectively reduces inflammation and significantly lowers the levels of NSE and Th17.
万方数据
维普
